Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Gilead Sciences, Inc.

Medarex Inc.

Oxford Biotherapeutics Ltd

Michelle Renee Kuhne

Alan J Korman

Guodong Chen

Paul O Sheppard

Mark J Selby

Josephine M Cardarelli

Richard Y Huang

Brigitte Devaux

Michelle Minhua Han

Huiming Li

Ekaterina G Deyanova

Xiao Min Schebye

Christine Bee

Daniel F Ardourel

Andy X Deng

Anan Chuntharapai

Peter Brams

Dawn M Tanamachi

Hong-An Truong

Haichun Huang

Chin Pan

Mohan Srinivasan

Nicholas Stuart Wilson

Pavel Strop

Jonathan Alexander Terrett

Robert F Graziano

Sarah Lee Pogue

Chetana Rao-Naik

Brian A Carr

Matthew Robert Schenauer

Richard Yu-Cheng Huang

Natalie Bezman

Manuel Baca

Magdeleine S Hung

Manu Kanwar

Erika Meaddough

Douglas S Rehder

Hong-An Troung

Yiming Yin

Peter Sung Keun Lee

Gamze Ozlem Camdere

Alexandre Ambrogelly

Hon Man Hamlet Chu

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.

Human monoclonal antibodies that bind CXCR4 and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.

FLT3L-FC fusion proteins

The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.

Treatment of hematologic malignancies with an anti-CXCR4 antibody

Nucleic acids encoding human monoclonal antibodies that bind CXCR4

The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.

Antibodies

Human monoclonal antibodies that bind CXCR4

Growing community of inventors

San Francisco, CA, United States of America

Michelle Renee Kuhne